Anavex Life Sciences Corp (OTCMKTS:AVXL) is one of the prominent name in the industry of biopharmaceuticals. The company develops the drug candidates to cure Alzheimer and other central nervous diseases. Recently, the company announced that it included Jacqueline French to its Scientific Advisory Board. She is a recognized expert on innovative therapeutic interventions, epilepsy and clinical trial methodology.
The Chief Executive Officer of Anavex, Christopher U. Missling, said that the board is excited to welcome French as a Scientific Advisor. Her contribution to develop innovative epilepsy treatments has been significant. She is known for pioneering the clinical care of seizures. The management firmly believes French’s expertise and her experience in neurology will add significant value as the company advance with development activities of its lead drug candidate ANAVEX 2-73.
The areas of expertise
Anavex Life stated that Dr. French plays a vital and influential leadership role in the area of formulation of new therapeutics for epilepsy. She takes care of a symposium on trial design and its results and holds key positions on committees of the AAN, where she has co-authored various AAN clinical practice guidelines. Dr. French has written various research articles, editorials and chapters, and has been featured in world-famous publications. She has edited two books focused on epilepsy and is a global presenter on antiepileptic drug therapeutics and linked topics.
The development work
Dr. French said that she is highly impressed with the positive initial epilepsy results for ANAVEX 2-73, which shows a significant reduction in anti-seizure effectiveness as compared to three currently accepted epilepsy medications as well as noteworthy synergy with each of these epilepsy drugs. ANAVEX 2-73 was demonstrated to be harmless in a Phase 1 human trial, which is supportive of next-general epilepsy treatments. She added that she look forward to collaborating with Anavex and its team of scientific advisors as together they work to develop ANAVEX 2-73.